v3.26.1
Related party transactions (Tables)
12 Months Ended
Dec. 31, 2025
Related party transactions [abstract]  
Disclosure of key management personnel compensation
For each of the periods presented, the following compensation was granted to the members of the Leadership Team of the Company and were recognized as expense:
Year ended December 31,
(in thousands of euro)202320242025
Personnel expenses and other short-term employee benefits2,856 3,835 3,490 
Extra pension benefits33 166 (37)
Share-based compensation2,081 2,302 925 
Advisory fees 471 — — 
Executive Committee & Board members compensation5,441 6,303 4,377 
Disclosure of transactions between related parties The payments between the two companies as well as the liabilities and receivables as of December 31, 2025 are as follows:
As of December 31, 2025
(in thousands of euros)PaymentsUpcoming payments
Collection (AstraZeneca towards the Company) / Receivables2,003 565 
Payments (the Company towards AstraZeneca) / Liabilities(4,978)(1,568)
Total
(2,975)(1,003)
Sanofi invested €15.0 million in capital on April 23, 2025, representing 9.05% of total shares. Sanofi is related to the company through two collaboration agreements. With the exception of the capital investment, the company had no financial transactions during the 2025 financial year.
Other balance sheet items relating to related parties are disclosed in Note 13.